{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:22:22Z","timestamp":1790036542089,"version":"4.0.1"},"reference-count":27,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urol Int"],"published-print":{"date-parts":[[2014]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Objective:&lt;\/i&gt;&lt;\/b&gt; To present a systematic review assessing the efficacy and safety of mirabegron for overactive bladder (OAB). &lt;b&gt;&lt;i&gt;Materials and Methods:&lt;\/i&gt;&lt;\/b&gt; A literature search was performed using the Cochrane Library, MEDLINE, EMBASE and Science Citation Index Expanded. The literature reviewed included meta-analyses, randomized and nonrandomized prospective studies. We utilized mean difference (MD) to measure the mean number of incontinence episodes and the mean number of micturitions, and OAB questionnaire (OAB-q) and odds ratio (OR) to measure adverse events rates. We used the Cochrane Collaboration's Review Manager 5.1 software for statistical analysis. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; We identi&amp;#xFB01;ed six publications that strictly met our eligibility criteria. Meta-analysis of extractable data showed that mirabegron was more effective than placebo in treating OAB despite different drug dosages in the efficacy end points: mean number of incontinence episodes per 24 h (MD -0.54; 95% CI -0.63, -0.45; p = 0.001), mean number of micturitions per 24 h (MD -0.55; 95% CI -0.63, -0.47; p = 0.001), OAB-q (MD -4.49; 95% CI -6.27, -2.71; p = 0.001) and adverse events (OR 0.99; 95% CI 0.83, 1.19; p = 0.92). When compared to tolterodine, mirabegron was more effective in terms of mean number of incontinence episodes per 24 h (MD -0.25; 95% CI -0.43, -0.06; p = 0.009). However, there were no differences between mirabegron and tolterodine in mean number of micturitions per 24 h (MD -0.17; 95% CI -0.35, 0.01; p = 0.07) and OAB-q (MD -1.09; 95% CI -2.51, 0.33; p = 0.13). Mirabegron also had a lower adverse reaction rate (OR 0.9; 95% CI 0.8, 1.0; p = 0.04). &lt;b&gt;&lt;i&gt;Conclusions:&lt;\/i&gt;&lt;\/b&gt; In this diverse population, mirabegron was an effective and safe pharmacologic therapy for OAB.<\/jats:p>","DOI":"10.1159\/000361079","type":"journal-article","created":{"date-parts":[[2014,8,7]],"date-time":"2014-08-07T07:25:31Z","timestamp":1407396331000},"page":"326-337","source":"Crossref","is-referenced-by-count":37,"title":["The Role of Mirabegron in Overactive Bladder: A Systematic Review and Meta-Analysis"],"prefix":"10.1159","volume":"93","author":[{"given":"Tao","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Xi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan-Du","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Yuan","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2014,8,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.10052"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.11.021"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02228.x"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-002-0301-4"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.09.019"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-2838(03)00045-9"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2011.542146"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0086-3"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/1756287209103937"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.115840"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-013-2042-x"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22373"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2013.02.077"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.10.016"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.10.017"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.10.048"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/9780470712184.fmatter"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2011.03.014"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2012.0254"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-013-2161-4"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-013-0509-9"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-006-0229-0"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.06.047"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2011.03473.x"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.08.060"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e2365"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12194"}],"container-title":["Urologia Internationalis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/361079","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/361079","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T17:35:42Z","timestamp":1745429742000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000361079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,10,1]]},"published-print":{"date-parts":[[2014,10,9]]}},"URL":"https:\/\/doi.org\/10.1159\/000361079","archive":["Portico"],"relation":{},"ISSN":["0042-1138","1423-0399"],"issn-type":[{"value":"0042-1138","type":"print"},{"value":"1423-0399","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}